Menu

Celyad Completes $100 Million IPO

Boston – July 27, 2015 – Cooley advised the underwriters on Celyad SA's initial public offering of American Depositary Shares (ADSs) and concurrent private placement in Europe. Celyad, based in Belgium, is a clinical-stage specialty biopharmaceutical company focused on changing the fields of cardiology and oncology by developing novel cell therapy treatment platforms called C-Cure and CAR-NKG2D. The company's ADSs trade on The NASDAQ Global Market under the symbol "CYAD."

UBS Securities LLC and Piper Jaffray & Co. acted as joint book-running managers of the global offering and as representatives of the several underwriters, including Petercam NV/SA, Bryan, Garnier & Co., LifeSci Capital, LLC and Lake Street Capital Markets, LLC.

About Cooley LLP

High-growth and established companies, investors and investment banks focused on technology and life sciences partner with Cooley on transformative deals and high-stakes matters, where innovation meets the law.

Cooley has 850 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Kenneth Krisko  Partner Reston, Boston
Marc Recht  Partner Boston
Natasha Leskovsek  Of Counsel Washington, DC
Bill Christiansen  Partner Seattle
Phil Mitchell  Partner New York
Giselle Rivers  Partner Boston, New York
Div Gupta  Partner New York
Richard Segal  Partner New York